Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Brookline, Massachusetts Clinical Trials

A listing of Brookline, Massachusetts clinical trials actively recruiting patient volunteers.

RESULTS

Found (126) clinical trials

AGN-241751 in the Treatment of Major Depressive Disorder

To evaluate the efficacy at 1 day post initial oral dose of AGN-241751 compared with placebo in participants with MDD

Phase

2.97 miles

Learn More »

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

Phase

2.97 miles

Learn More »

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.

Phase

3.11 miles

Learn More »

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).

Phase

3.11 miles

Learn More »

The "Reach For Health" Program: Delaying Sexual Activity in Children

Given the early age of sexual initiation among urban minority youth, interventions aimed at reducing sexual initiation and risky sexual behavior related to HIV and other sexually transmitted infections (STIs) should begin prior to entry into middle school. These interventions should support both students and their parents through the transition ...

Phase

3.16 miles

Learn More »

Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection

PRIMARY OBJECTIVES: I. To define the proportion of participants who develop treatment failure at 2 years, defined as the occurrence of distant or any nodal metastases or recurrence of cancer requiring chemotherapy (CMT), defined as a cancer that no longer meets the definition of superficially invasive squamous cell carcinoma (SISCCA) ...

Phase

3.35 miles

Learn More »

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

PRIMARY OBJECTIVES: I. To determine if there is a signal for an increase in complete response (CR) rate in the measurable brain metastases at 12 weeks post radiation therapy (RT) (whole brain or stereotactic radiosurgery [SRS]) as determined by magnetic-resonance imaging (MRI) scan of the brain, with the addition of ...

Phase

3.35 miles

Learn More »

Cabozantinib S-Malate Crizotinib Savolitinib or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

PRIMARY OBJECTIVES: I. To compare progression-free survival (PFS) in patients with metastatic papillary renal cell carcinoma (mPRCC) treated with sunitinib malate (sunitinib) to PFS in patients with mPRCC treated with MET kinase inhibitors. SECONDARY OBJECTIVES: I. To compare Response Evaluation Criteria in Solid Tumors (RECIST) response rate (RR; defined as ...

Phase

3.35 miles

Learn More »

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

PRIMARY OBJECTIVES: I. To determine if dose-escalated and -intensified photon IMRT or proton beam therapy (using a dose-per-fraction escalation with simultaneous integrated boost) with concomitant and adjuvant temozolomide improves overall survival, as compared to standard-dose photon irradiation with concomitant and adjuvant temozolomide. SECONDARY OBJECTIVES: I. To indirectly compare dose-escalated and ...

Phase

3.35 miles

Learn More »

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

GSK2330811 is a humanized monoclonal antibody which is in development for systemic sclerosis (SSc), a rare autoimmune disease with high morbidity and mortality. Currently, there are no approved disease modifying therapies and it is an area of high unmet medical need. GSK2330811 has been shown to bind and neutralize Oncostatin ...

Phase

3.35 miles

Learn More »